{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:11:04Z","timestamp":1762506664515,"version":"3.40.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.dld.2015.10.023","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T13:46:56Z","timestamp":1446299216000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-3615","authenticated-orcid":false,"given":"Cristina","family":"Guiotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-4487","authenticated-orcid":false,"given":"Francesco","family":"Frigerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Vizzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Cerruti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ercole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Cosimato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Lavagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Migliardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2015.10.023_bib0190","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"6","author":"Dignass","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2015.10.023_bib0195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2015.10.023_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2015.10.023_bib0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2015.10.023_bib0210","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.10.023_bib0225","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"Journal of American Medical Association"},{"key":"10.1016\/j.dld.2015.10.023_bib0230","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","article-title":"Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD","volume":"21","author":"Zitomersky","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2015.10.023_bib0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0240","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ibd.21839","article-title":"Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease","volume":"18","author":"Pariente","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2015.10.023_bib0245","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.10.023_bib0250","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2003.50182","article-title":"Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize","volume":"124","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0255","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial","volume":"109","author":"Steenholdt","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0260","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0265","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.crohns.2008.05.011","article-title":"Management of loss of response to anti-TNF drugs: change the dose or change the drug?","volume":"2","author":"Van Assche","year":"2008","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2015.10.023_bib0270","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.033","article-title":"Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.10.023_bib0280","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2015.10.023_bib0290","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0295","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","author":"Vande Casteele","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/gut.2009.191411","article-title":"Predicting the response to infliximab from trough serum levels","volume":"59","author":"Rutgeerts","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0305","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jech.40.3.274","article-title":"Comparison of methods of measuring blood pressure","volume":"40","author":"Altman","year":"1986","journal-title":"Journal of Epidemiology and Community Health"},{"key":"10.1016\/j.dld.2015.10.023_bib0310","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.317.7155.409","article-title":"Generalisation and extrapolation","volume":"317","author":"Altman","year":"1998","journal-title":"British Medical Journal"},{"key":"10.1016\/j.dld.2015.10.023_bib0315","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I","volume":"21","author":"Passing","year":"1983","journal-title":"Journal of Clinical Chemistry and Clinical Biochemistry"},{"key":"10.1016\/j.dld.2015.10.023_bib0320","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.dld.2015.10.023_bib0325","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0330","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2015.10.023_bib0335","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.crohns.2014.01.009","article-title":"Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment","volume":"8","author":"Marits","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.dld.2015.10.023_bib0340","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1007\/s00216-013-7154-0","article-title":"A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study","volume":"405","author":"Corstjens","year":"2013","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/j.dld.2015.10.023_bib0345","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis","volume":"64","author":"Wolbink","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2015.10.023_bib0350","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0355","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2015.10.023_bib0360","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2015.10.023_bib0365","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10620-012-2504-x","article-title":"Understanding infliximab in Crohn's disease: the long-term outcomes","volume":"58","author":"Turner","year":"2013","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.dld.2015.10.023_bib0370","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/MIB.0000000000000037","article-title":"Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"20","author":"Paul","year":"2014","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815006878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865815006878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:32:49Z","timestamp":1537230769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865815006878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1590865815006878"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2015.10.023","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2015.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}